Revenue
2018
2019
2020
2021
2022
2023
2024
2025
CORCEPT THERAPEUTICS INC (CORT)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $761.4M | $675.0M | $482.4M | $401.9M | $366.0M | $353.9M | $306.5M | $251.2M | $159.2M | $81.3M | — | — | — | — | — | — | $29,000 | — | — | — | — | — | — | — | — | — |
| Research & development | $254.9M | $246.9M | $184.4M | $131.0M | $113.9M | $114.8M | $89.0M | $75.2M | $40.4M | $23.8M | $15.4M | $18.4M | $20.5M | $14.1M | $21.0M | $18.9M | $14.4M | — | — | — | — | — | — | — | — | — |
| Operating expenses | — | — | — | — | — | — | — | — | — | — | — | $54.2M | $51.9M | $39.6M | $32.3M | $27.4M | $20.3M | — | — | — | — | — | — | — | — | — |
| Operating income | $44.8M | $137.0M | $107.3M | $112.6M | $124.5M | $128.2M | $111.6M | $89.5M | $52.9M | $10.2M | −$3.4M | −$27.6M | −$41.5M | −$36.3M | −$32.3M | −$27.4M | −$20.3M | — | — | — | — | — | — | — | — | — |
| EBITDAderived | $45.9M | $137.7M | $108.3M | $113.9M | $125.5M | $128.7M | $112.3M | $89.7M | $53.0M | $10.3M | −$3.3M | −$27.5M | −$41.4M | −$36.2M | −$32.3M | −$27.4M | −$20.2M | — | — | — | — | — | — | — | — | — |
| Net income | $99.7M | $141.2M | $106.1M | $101.4M | $112.5M | $106.0M | $94.2M | $75.4M | $129.1M | $8.1M | −$6.4M | −$31.4M | −$46.0M | −$38.0M | −$32.4M | −$26.0M | −$20.2M | −$20.1M | −$11.6M | −$24.9M | −$20.1M | −$15.5M | −$9.8M | −$18.5M | −$7.5M | −$1.8M |
| Basic EPSper diluted share | $0.95 | $1.35 | $1.02 | $0.95 | $0.97 | $0.92 | $0.82 | $0.65 | $1.14 | $0.07 | -$0.06 | -$0.31 | -$0.46 | -$0.41 | -$0.39 | -$0.38 | -$0.38 | — | — | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 | $0.85 | $0.77 | $0.60 | $1.04 | $0.07 | -$0.06 | -$0.31 | -$0.46 | -$0.41 | -$0.39 | -$0.38 | -$0.38 | — | — | — | — | — | — | — | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 17, 2026Form 4 | MAHONEY DAVID LDirector | SellCommon Stock · indirect | 20.0K | $84.53 | $1.69M | 26.1K |
| Jun 16, 2026Form 4 · 10b5-1 | WILSON JAMES NDirector | SellCommon Stock · indirect | 5.8K | $83.57 | $486.6K | 1.09M |
| Jun 16, 2026Form 4 · 10b5-1 | WILSON JAMES NDirector | SellCommon Stock · indirect | 4.2K | $82.69 | $345.4K | 1.10M |
| Jun 15, 2026Form 4 · 10b5-1 | Mokari AtabakChief Financial Officer | SellCommon Stock | 2 | $82.45 | $164.90 | 16.1K |
| Jun 15, 2026Form 4 · 10b5-1 | Mokari AtabakChief Financial Officer | SellCommon Stock | 19.5K | $81.81 | $1.59M | 16.1K |